GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KORU Medical Systems Inc (NAS:KRMD) » Definitions » Total Assets

KRMD (KORU Medical Systems) Total Assets : $27.39 Mil (As of Sep. 2024)


View and export this data going back to 1996. Start your Free Trial

What is KORU Medical Systems Total Assets?

KORU Medical Systems's Total Assets for the quarter that ended in Sep. 2024 was $27.39 Mil.

Warning Sign:

If a company builds assets at 26.4% a year, faster than its revenue growth rate of 5.1% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, KORU Medical Systems's average Total Assets Growth Rate was -24.40% per year. During the past 3 years, the average Total Assets Growth Rate was 10.40% per year. During the past 5 years, the average Total Assets Growth Rate was 26.40% per year. During the past 10 years, the average Total Assets Growth Rate was 22.50% per year.

During the past 13 years, KORU Medical Systems's highest 3-Year average Total Assets Growth Rate was 46.00%. The lowest was -11.80%. And the median was 16.00%.

Total Assets is connected with ROA %. KORU Medical Systems's annualized ROA % for the quarter that ended in Sep. 2024 was -23.13%. Total Assets is also linked to Revenue through Asset Turnover. KORU Medical Systems's Asset Turnover for the quarter that ended in Sep. 2024 was 0.30.


KORU Medical Systems Total Assets Historical Data

The historical data trend for KORU Medical Systems's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KORU Medical Systems Total Assets Chart

KORU Medical Systems Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.88 39.92 41.29 42.33 28.46

KORU Medical Systems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.35 28.46 27.50 27.30 27.39

KORU Medical Systems Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

KORU Medical Systems's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=20.354+8.107
=28.46

KORU Medical Systems's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=17.733+9.657
=27.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KORU Medical Systems  (NAS:KRMD) Total Assets Explanation

Total Assets is connected with ROA %.

KORU Medical Systems's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-6.324/( (27.304+27.39)/ 2 )
=-6.324/27.347
=-23.13 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

KORU Medical Systems's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=8.18/( (27.304+27.39)/ 2 )
=8.18/27.347
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

KORU Medical Systems Total Assets Related Terms

Thank you for viewing the detailed overview of KORU Medical Systems's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


KORU Medical Systems Business Description

Traded in Other Exchanges
N/A
Address
100 Corporate Drive, Mahwah, NJ, USA, 07430
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Executives
Manko Joseph M. Jr. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Kenneth E Miller officer: Chief Commercial Officer 26 MOUNTAINVIEW RD, WARREN NJ 07059
Edward Wholihan director C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Linda M Tharby officer: President and CEO BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
Lafrence Andrew D.c. officer: Chief Financial Officer C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas Edward Adams officer: Interim CFO 524 WOODLAND AVENUE, BRIELLE NJ 08730
Brian Case officer: Chief Technology Officer 424 CYPRUS CIR, LAKE VILLA IL 60046-8629
Shahriar Matin director 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Donna French director 25 SEARSVILLE COURT, HILLSBOROUGH CA 94010
Donald B Pettigrew officer: Pres./Chief Commercial Officer 7871 ENGEN LOOP, PARK CITY UT 84098
Karen Fisher officer: CFO 24 CARPENTER ROAD, CHESTER NY 10918
Daniel S Goldberger director 24 CARPENTER ROAD, CHESTER NY 10918
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Horton Freedom, L.p. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103